CD133/Prominin-1-Mediated Autophagy and Glucose Uptake Beneficial for Hepatoma Cell Survival

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Chen, Haiyang ^a   Luo, Zaili ^a   Dong, Liwei ^a   Tan, Yexiong ^a   Yang, Jiamei ^a   Feng, Gensheng ^b   Wu, Mengchao ^a   Li, Zhong ^a,c   Wang, Hongyang ^a,d  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ZHENGZHOU UNIVERSITY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CD133 ANTIGEN; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN LIGHT CHAIN 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL MEMBRANE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL SURVIVAL; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; ENERGY METABOLISM; GLUCOSE TRANSPORT; HEPATOMA CELL; IMMUNOFLUORESCENCE MICROSCOPY; LIVER CARCINOGENESIS; LYSOSOME; MALE; MOUSE; NONHUMAN; TIME LAPSE IMAGING; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; APOPTOSIS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; GLUCOSE; GLYCOPROTEINS; HUMANS; LIVER NEOPLASMS; LYSOSOMES; MALE; MICE; PEPTIDES; PHAGOSOMES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84874284569     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056878     Document Type: Article

References (57)

1. Mizrak D, Brittan M, Alison MR, (2008) CD133: molecule of the moment. J Pathol 214: 3-9.
2. Broder CC, Collman RG, (1997) Chemokine receptors and HIV. J Leukoc Biol 62: 20-29.
3. Yin S, Li J, Hu C, Chen X, Yao M, et al. (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450.
4. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, et al. (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351: 820-824.
5. Song W, Li H, Tao K, Li R, Song Z, et al. (2008) Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62: 1212-1218.
6. Ma S, Chan KW, Hu L, Lee TK, Wo JY, et al. (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556.
7. Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, et al. (2010) miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7: 694-707.
8. Bourseau-Guilmain E, Griveau A, Benoit JP, Garcion E, (2011) The Importance of the Stem Cell Marker Prominin-1/CD133 in the Uptake of Transferrin and in Iron Metabolism in Human Colon Cancer Caco-2 Cells. PLoS One 6: e25515.
9. Bakondi B, Shimada IS, Peterson BM, Spees JL, (2011) SDF-1alpha secreted by human CD133-derived multipotent stromal cells promotes neural progenitor cell survival through CXCR7. Stem Cells Dev 20: 1021-1029.
10. Yang Z, Wang Z, Fan Y, Zheng Q, (2012) Expression of CD133 in SW620 colorectal cancer cells is modulated by the microenvironment. Oncol Lett 4: 75-79.
11. Al-Hajj M, (2007) Cancer stem cells and oncology therapeutics. Curr Opin Oncol 19: 61-64.
12. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB, (2001) Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2: 82-91.
13. Lardon J, Corbeil D, Huttner WB, Ling Z, Bouwens L, (2008) Stem cell marker prominin-1/AC133 is expressed in duct cells of the adult human pancreas. Pancreas 36: e1-6.
14. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, et al. (2008) CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 118: 2111-2120.
15. Zacchigna S, Oh H, Wilsch-Brauninger M, Missol-Kolka E, Jaszai J, et al. (2009) Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration. J Neurosci 29: 2297-2308.
16. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Benos DJ, et al. (2008) CD133 is a marker of bioenergetic stress in human glioma. PLoS One 3: e3655.
17. Spee B, Carpino G, Schotanus BA, Katoonizadeh A, Vander Borght S, et al. (2010) Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut 59: 247-257.
18. Corbo C, Orru S, Gemei M, Noto RD, Mirabelli P, et al. (2012) Protein cross-talk in CD133+ colon cancer cells indicates activation of the Wnt pathway and upregulation of SRp20 that is potentially involved in tumorigenicity. Proteomics 12: 2045-2059.
19. Zhang C, Xu Y, Zhao J, Fan L, Jiang G, et al. (2011) Elevated Expression of the Stem Cell Marker CD133 Associated with Line-1 Demethylation in Hepatocellular Carcinoma. Ann Surg Oncol 18: 2373-2380.
20. Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, et al. (2008) Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 18: 1037-1046.
21. Zhang L, Sun H, Zhao F, Lu P, Ge C, et al. (2012) BMP4 Administration Induces Differentiation of CD133+ Hepatic Cancer Stem Cells, Blocking Their Contributions to Hepatocellular Carcinoma. Cancer Res 72: 4276-4285.
22. Zhang J, Luo N, Luo Y, Peng Z, Zhang T, et al. (2012) microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb. Int J Oncol 40: 747-756.
23. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, et al. (2012) CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology 55: 807-820.
24. Mak AB, Nixon AM, Moffat J, (2012) The mixed lineage leukemia (MLL) fusion-associated gene AF4 promotes CD133 transcription. Cancer Res 72: 1929-1934.
25. Bauer N, Wilsch-Brauninger M, Karbanova J, Fonseca AV, Strauss D, et al. (2011) Haematopoietic stem cell differentiation promotes the release of prominin-1/CD133-containing membrane vesicles-a role of the endocytic-exocytic pathway. EMBO Mol Med 3: 398-409.
26. Rappa G, Fodstad O, Lorico A, (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26: 3008-3017.
27. Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, et al. (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99: 100-109.
28. Damek-Poprawa M, Volgina A, Korostoff J, Sollecito TP, Brose MS, et al. (2011) Targeted inhibition of CD133+ cells in oral cancer cell lines. J Dent Res 90: 638-645.
29. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY, (2008) CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27: 1749-1758.
30. Lomonaco SL, Finniss S, Xiang C, Decarvalho A, Umansky F, et al. (2009) The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 125: 717-722.
31. Fu X, Tan D, Hou Z, Hu Z, Liu G, et al. (2012) The effect of miR-338-3p on HBx deletion-mutant (HBx-d382) mediated liver-cell proliferation through CyclinD1 regulation. PLoS One 7: e43204.
32. Li Y, Tang Y, Ye L, Liu B, Liu K, et al. (2003) Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol 129: 43-51.
33. Li Z, Dong X, Wang Z, Liu W, Deng N, et al. (2005) Regulation of PTEN by Rho small GTPases. Nat Cell Biol 7: 399-404.
34. Mizushima N, Yoshimori T, Levine B, (2010) Methods in mammalian autophagy research. Cell 140: 313-326.
35. Salemi S, Yousefi S, Constantinescu MA, Fey MF, Simon HU, (2012) Autophagy is required for self-renewal and differentiation of adult human stem cells. Cell Res 22: 432-435.
36. Wang RC, Levine B, (2010) Autophagy in cellular growth control. FEBS Lett 584: 1417-1426.
37. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, et al. (2000) The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 275: 5512-5520.
38. Maw MA, Corbeil D, Koch J, Hellwig A, Wilson-Wheeler JC, et al. (2000) A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 9: 27-34.
39. Marzesco AM, Janich P, Wilsch-Brauninger M, Dubreuil V, Langenfeld K, et al. (2005) Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 118: 2849-2858.
40. Corbeil D, Marzesco AM, Wilsch-Brauninger M, Huttner WB, (2010) The intriguing links between prominin-1 (CD133), cholesterol-based membrane microdomains, remodeling of apical plasma membrane protrusions, extracellular membrane particles, and (neuro)epithelial cell differentiation. FEBS Lett 584: 1659-1664.
41. Eskelinen EL, (2011) The dual role of autophagy in cancer. Curr Opin Pharmacol 11: 294-300.
42. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, et al. (2011) Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 17: 654-666.
43. Vessoni AT, Muotri AR, Okamoto OK, (2012) Autophagy in stem cell maintenance and differentiation. Stem Cells Dev 21: 513-520.
44. Oliver L, Hue E, Priault M, Vallette FM (2012) Basal Autophagy Decreased During the Differentiation of Human Adult Mesenchymal Stem Cells. Stem Cells Dev.
45. Zhang Q, Yang YJ, Wang H, Dong QT, Wang TJ, et al. (2012) Autophagy activation: a novel mechanism of atorvastatin to protect mesenchymal stem cells from hypoxia and serum deprivation via AMP-activated protein kinase/mammalian target of rapamycin pathway. Stem Cells Dev 21: 1321-1332.
46. Rausch V, Liu L, Apel A, Rettig T, Gladkich J, et al. (2012) Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment. J Pathol 227: 325-335.
47. Angelastro JM, Lame MW, (2010) Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res 8: 1105-1115.
48. Ding W, Mouzaki M, You H, Laird JC, Mato J, et al. (2009) CD133+ liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology 49: 1277-1286.
49. Piao LS, Hur W, Kim TK, Hong SW, Kim SW, et al. (2012) CD133(+) liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 315: 129-137.
50. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, et al. (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65: 4320-4333.
51. Zobalova R, McDermott L, Stantic M, Prokopova K, Dong LF, et al. (2008) CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP. Biochem Biophys Res Commun 373: 567-571.
52. Dubreuil V, Marzesco AM, Corbeil D, Huttner WB, Wilsch-Brauninger M, (2007) Midbody and primary cilium of neural progenitors release extracellular membrane particles enriched in the stem cell marker prominin-1. J Cell Biol 176: 483-495.
53. Huttner HB, Janich P, Kohrmann M, Jaszai J, Siebzehnrubl F, et al. (2008) The stem cell marker prominin-1/CD133 on membrane particles in human cerebrospinal fluid offers novel approaches for studying central nervous system disease. Stem Cells 26: 698-705.
54. Fargeas CA, Karbanova J, Jaszai J, Corbeil D, (2011) CD133 and membrane microdomains: old facets for future hypotheses. World J Gastroenterol 17: 4149-4152.
55. Simons K, Toomre D, (2000) Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1: 31-39.
56. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, et al. (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106: 16281-16286.
57. Yang Z, Zhang L, Ma A, Liu L, Li J, et al. (2011) Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations. PLoS One 6: e28405.